Good day, welcome to the Intellia Therapeutics Incorporated 2019 Annual Meeting of Stockholders. I would now like to turn the conference over to Perry Karsen, Chairman of the company's Board of Directors, to proceed with the 2019 Annual Meeting of Stockholders. Mr. Karsen, please go ahead.
Thank you. Good morning. I am Perry Karsen, Chairman of the Board of Intellia Therapeutics, Inc., I will act as Chairman of this meeting. I am pleased to welcome you to the Intellia 2019 Annual Meeting of Stockholders. Before I call the meeting to order, I would like to introduce you to members of our Board and our executive team who are with us today. The other members of the Board with us today are Caroline Dorsa, Dr. Jesse Goodman, Dr. John M. Leonard, our President and Chief Executive Officer, and Dr. Frank Verwiel. The other Executive Officers of the company with us today are Glenn Goddard, Executive Vice President and Chief Financial Officer, José Rivera, Executive Vice President, General Counsel, and Corporate Secretary, and Dr. Andrew Schiermeier, Executive Vice President, development and corporate strategy. Mr. Rivera will act as Secretary of this meeting.
I would also like to introduce Sarah Albano of Deloitte & Touche LLP, the company's independent registered public accounting firm, who is available to respond to appropriate questions. The meeting will now officially come to order. We propose to proceed with the formal business of the meeting as set forth in the company's 2019 notice of annual meeting and proxy statement. Following the formal meeting, we will give you an opportunity to ask any questions you may have. Will the Secretary please report at this time with respect to the mailing of the notice of the meeting and the stockholders list?
I have at this meeting a complete list of the stockholders of record of the company at the close of business on April 1st, 2019, the record date for this meeting. I also have with me an affidavit certifying that commencing on April 16th, 2019, a proxy card, proxy statement, notice of meeting, annual report of the company, and return mail envelope were deposited in the United States Mail to all stockholders of record as of April 1st, 2019.
At this time, I'd like to introduce Dr. Nishla Keiser, Senior Vice President and Deputy General Counsel, who has been appointed to act as inspector of elections at this meeting. Dr. Keiser has taken and subscribed the customary oath of office to execute her duties with strict impartiality, which will be filed with the records of the meeting. Her function is to decide upon the qualifications of voters, accept their votes, and when balloting on all matters is completed, to tally the final votes. Will the secretary please report at this time with respect to the existence of a quorum?
I have been informed by the inspector of elections that proxies have been received for 40,766,717 shares of the 45,479,098 shares of common stock outstanding on the record date, which represents approximately 89.63% of the total number of shares entitled to vote at this meeting. This constitutes a quorum for the meeting today. We may now carry out the official business of the meeting. Are there any additional proxies to be submitted to the inspector of elections at this time? Mr. Chairman, there are no additional proxies to be submitted to the inspector of elections at this time.
We will now proceed with the formal business of this meeting. The following proposals are to be considered by our stockholders at this meeting. Proposal one is the election of directors. Election of the following individuals nominated to serve as Class III directors for a three-year term ending at the annual meeting of stockholders to be held in 2022. Caroline Dorsa, Perry Karsen, Dr. John Leonard. Proposal two is the ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the company for the fiscal year ending December 31st, 2019. Proposal three is the approval on an advisory basis of the compensation of the named executive officers. Proposal four is the advisory vote on the frequency of advisory votes on executive compensation. Those were the final proposals for today's meeting.
Dr. Leonard, Mr. José Rivera, and Mr. Goddard were designated as proxies by certain stockholders. Such shares represented by proxy will be voted in accordance with the instructions given. If no instructions were given, such shares will be voted for the nominees listed in Proposal one, for Proposal two, for Proposal three, and for one year on Proposal four. The secretary will now describe the voting procedures.
The time is 9:07 A.M. Eastern Time on Tuesday, May 21st, 2019, the polls are now open for voting on the proposals described by the chairman. Voting is by proxy and written ballot. You do not need to vote again if you have already voted your proxy online, by telephone, or by mail. Is there anyone present, whether or not you already submitted a proxy, who now wants to complete the ballot virtually? The time is 9:07 A.M. Eastern Time, the polls are now closed for voting.
May we have the results of the voting?
The report of the Inspector of Elections covering the proposals presented at this meeting is as follows. Proposal one for the election of the following individuals, Caroline Dorsa, Perry Karsen, and John Leonard as Class III directors of the company is carried. Proposal two, for the ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the company for the fiscal year ending December 31st, 2019, has been approved. Proposal three, for the approval on an advisory basis of the compensation of the named executive officers, has been approved. Proposal four, the advisory vote on the frequency of advisory votes on executive compensation has been approved for one year.
Thank you. There being no other business to properly come before this meeting, let us pause for a moment to compile any questions that have been submitted via the online portal regarding only the matters that have been discussed in this formal portion of the annual meeting. We will allow one to two follow-up questions per submission. Will the secretary please advise if we have any questions?
We have no questions appropriately related to the purpose of this meeting.
There being no other business to properly come before this meeting, this meeting is now adjourned. Thank you for attending Intellia Therapeutics Inc. 2019 Annual Meeting of Stockholders.
The 2019 Annual Meeting of Stockholders has now concluded. Thank you for attending today's meeting and presentation.